Tengion, which is developing functional neo-organs using a patient's own cells, will see its quiet period end on Tuesday, May 18th. On April 4th, the company raised $30 million by offering 6 million shares at $5, below the range of $8-$10. Piper Jaffray and...read more
Tengion, which is developing functional neo-organs using a patient's own cells, raised $30 million by offering 6 million shares at $5. The East Norriton, PA-based biotech had originally planned to raise $40 million by offering 4.4 million shares at a range of...read more
Tengion, which creates functional neo-organs using a patient's own cells with a urologic treatment in Phase 2, announced terms for its IPO on Wednesday. The East Norriton, PA-based company plans to raise $40 million by offering 4.4 million shares at a price...read more
Tengion quiet period ends May 18
Tengion, which is developing functional neo-organs using a patient's own cells, will see its quiet period end on Tuesday, May 18th. On April 4th, the company raised $30 million by offering 6 million shares at $5, below the range of $8-$10. Piper Jaffray and...read more
Tengion prices upsized IPO at $5.00, below the range
Tengion, which is developing functional neo-organs using a patient's own cells, raised $30 million by offering 6 million shares at $5. The East Norriton, PA-based biotech had originally planned to raise $40 million by offering 4.4 million shares at a range of...read more
4 IPOs planned for the week of Apr 5
The following IPOs are expected to price this week:
Metals USA Holdings (MUSA), the ninth largest metal distributor in the US, plans to raise $200 million by offering 10.5...read more
Regenerative medicine biotech Tengion announces IPO terms
Tengion, which creates functional neo-organs using a patient's own cells with a urologic treatment in Phase 2, announced terms for its IPO on Wednesday. The East Norriton, PA-based company plans to raise $40 million by offering 4.4 million shares at a price...read more